Compare Crispr Therapeutics AG (CRSP) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Raymond James Financial, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.55 (market cap $4.97B), while Raymond James Financial, Inc. trades at $170.7 (market cap $32.63B). The key difference: Raymond James Financial, Inc. is far larger — about 6.6× Crispr Therapeutics AG's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | RJF | |
|---|---|---|
Market Cap | $4.97B | $32.63B |
Sector | Health | Financials |
52-Week High | $76.78 | $176.43 |
52-Week Low | $44.34 | $140.89 |
Enterprise Value | $3.32B | — |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Raymond James Financial (RJF) trades at $166.98, down 0.68% on the day, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.83 surpassing expectations of $2.76, and revenue growth from $10.9B in 2022 to $13.84B in 2025. Analyst consensus is positive with a $176.83 price target, and recent news highlights momentum and dividend declarations.
The outlook for RJF remains favorable due to earnings momentum and analyst support, though risks include expense pressures and market volatility. Investment opportunity lies in its valuation below consensus target and dividend growth, but investors should monitor cost management and economic conditions that could impact financial services demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
